MedTrace Logo

Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation

NCT02995642 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-05-21

No results posted yet for this study

Summary

Stroke and abdominal aortic aneurysms (AAAs) are common and highly lethal vascular diseases. Angiogenesis and infiltration of inflammatory cells such as macrophages may cause stroke and AAAs.

The purpose of this study is to test PET/CT and PET/MRI imaging to specifically detect those diseases using a new developed agent (18F-FPPRGD2) that can target angiogenesis and macrophages.

Conditions

  • Aortic Aneurysm, Abdominal
  • Carotid Atherosclerosis

Interventions

DRUG

18F-FPPRGD2

One single intravenous injection.

DEVICE

Positron emission tomography

Undergo 18F-FPPRGD2 PET/CT or PET/MRI

PROCEDURE

Computed tomography

Undergo 18F-FPPRGD2 PET/CT or PET/MRI

DEVICE

Magnetic Resonance Imaging

Undergo 18F-FPPRGD2 PET/CT or PET/MRI

Sponsors & Collaborators

Principal Investigators

  • Michael V. McConnell, MD, MSEE · Stanford University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2020-09-30
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02995642 on ClinicalTrials.gov